Boston Therapeutics' New Tablet Reduces Sugar Intake for Diabetics

Boston Therapeutics has a new tablet PAZ320 designed to reduce a person's sugar intake by 40 percent. CEO Dr. David Platt believes the tablet will eventually be approved for non-diabetic patients looking to cut back on the copious amounts of sugar prevalent in many processed foods.